Clinical outcomes and safety of duloxetine and tolterodine combination in the treatment of mixed-type urinary incontinence: A single-arm retrospective study.

Abstract

ObjectiveThis study aimed to evaluate the clinical outcomes and safety of combined duloxetine and tolterodine therapy in patients with mixed urinary incontinence.MethodsA retrospective analysis was conducted on patients with mixed urinary incontinence treated between January 2021 and December 2023. Patients received tolterodine (4 mg/day) and duloxetine (40 mg twice daily). Clinical outcomes were assessed at weeks 4 and 12 using the Overactive Bladder Symptom Score, International Consultation on Incontinence Questionnaire-Short Form, pad tests, and bladder diaries. Patient satisfaction was evaluated using the Clinical Global Impression scale.ResultsThe study included 115 patients (mean age: 46.6 ± 13.4 years). Significant improvements were observed in Overactive Bladder Symptom Score, International Consultation on Incontinence Questionnaire-Short Form scores, and pad weights at weeks 4 and 12 compared to baseline (p < 0.001). Daily micturition, nocturia, urgency, and incontinence episodes significantly decreased, whereas mean voided volume increased. According to Clinical Global Impression scores, 73.9% of patients reported partial or complete improvement. Treatment-related adverse events were observed in 12.1% of patients.ConclusionThe combination therapy of duloxetine and tolterodine appears to be safe and potentially beneficial, reducing symptom scores and incontinence episodes. However, these findings need to be supported by controlled studies.